Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms: a randomized prospective study
Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms: a randomized prospective study
复制标题
DOI：
10.1097/01.gme.0000186663.36211.c0
复制
发表时间：
2006-05-01
影响因子：
2.7
通讯作者：
Hochner-Celnikier, Drorith
中科院分区：
文献类型：
--
作者：
Haimov-Kochman, Ronit;Barak-Glantz, Edyah;Hochner-Celnikier, Drorith
目的：为了探讨更年期症状的复发和严重程度后，两种方法的长期激素therapeutic.Design的中断：绝经后妇女接受激素治疗超过3年，并选择停止治疗被随机分配到两个治疗组。激素治疗突然（组1）或逐渐（组2）停止。在两组的症状进行了监测与格林更年期量表在1，3，6，9，12 months.Results：91名妇女年龄在48至73岁（平均年龄56.8 +/- 4.2岁）参加了这项研究。平均治疗持续时间为8.8 ± 3.8年。两组在绝经年龄、体重指数、开始治疗的原因、激素治疗持续时间、方案类型和停止激素治疗的原因方面没有差异。在停止治疗后，两组中相似比例的患者恢复激素治疗。更年期综合征，特别是血管功能障碍，更严重的第一组比第2组在激素治疗停药后的前3个月。然而，到6个月时，第2组的血管扩张症状更严重。到9至12个月时，未观察到组间差异。体重增加，阴道出血，萎缩的百分比停止治疗后，通过任一method.Conclusions：我们的具体方案，逐步停止激素治疗只是推迟，既不能防止也不能最大限度地减少，血管炎症状的复发，情绪恶化，性功能障碍，以及由此产生的不适。
Objective: To investigate the recurrence and severity of climacteric symptoms after two methods of discontinuation of prolonged hormone therapy.Design: Postmenopausal women treated with hormone therapy for more than 3 years and opting to discontinue therapy were randomly assigned to two treatment groups. Hormone therapy was discontinued either abruptly (group 1) or gradually (group 2). Symptoms in both groups were monitored with the Greene climacteric scale at 1, 3, 6, 9, and 12 months.Results: Ninety-one women aged 48 to 73 years (mean age 56.8 +/- 4.2 years) participated in the study. The mean therapy duration was 8.8 +/- 3.8 years. No differences were noted between the two groups regarding age at menopause, body mass index, reasons to start therapy, hormone therapy duration, type of regimen, and reasons cited for hormone treatment discontinuation. After cessation of therapy, a similar percentage of patients in each group resumed hormone therapy. Climacteric syndromes, specifically vasomotor dysfunction, were more severe in group I than in group 2 during the first 3 months after hormone therapy withdrawal. However, by 6 months vasomotor symptoms were worse in group 2. By 9 to 12 months, no difference was noted between groups. No differences were observed in the percentage of weight gain, vaginal bleeding, and atrophy after discontinuation of therapy by either method.Conclusions: Our specific regimen of gradual discontinuation of hormone therapy merely postponed, and neither prevented nor minimized, the reappearance of vasomotor symptoms, mood deterioration, and sexual dysfunction, and the resulting discomfort.